Lisata Therapeutics, Inc.
General ticker "LSTA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $21.7M (TTM average)
Lisata Therapeutics, Inc. follows the US Stock Market performance with the rate: 3.9%.
Estimated limits based on current volatility of 4.2%: low 1.87$, high 2.05$
Factors to consider:
- Total employees count: 26 (+4.0%) as of 2024
- Top business risk factors: Operational and conduct risks, Liquidity and credit risks, Labor/talent shortage/retention, Market competition, Cybersecurity threats
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.62$, 4.81$]
- 2025-12-31 to 2026-12-31 estimated range: [0.96$, 3.03$]
Financial Metrics affecting the LSTA estimates:
- Positive: with PPE of -1.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -80.44 <= 0.33
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 55.00 > -0.66
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
Short-term LSTA quotes
Long-term LSTA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $1.00MM |
| Operating Expenses | $57.60MM | $25.71MM | $23.41MM |
| Operating Income | $-57.60MM | $-25.71MM | $-22.41MM |
| Non-Operating Income | $0.90MM | $2.54MM | $1.63MM |
| R&D Expense | $43.46MM | $12.73MM | $11.33MM |
| Income(Loss) | $-56.70MM | $-23.17MM | $-20.78MM |
| Taxes | $-2.48MM | $-2.33MM | $-0.80MM |
| Profit(Loss)* | $-54.23MM | $-20.84MM | $-19.98MM |
| Stockholders Equity | $66.58MM | $48.15MM | $29.57MM |
| Assets | $73.03MM | $54.69MM | $35.00MM |
| Operating Cash Flow | $-21.17MM | $-20.03MM | $-19.36MM |
| Capital expenditure | $0.28MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $28.91MM | $10.10MM | $13.23MM |
| Financing Cash Flow | $-0.22MM | $0.39MM | $-0.21MM |
| Earnings Per Share** | $-10.47 | $-2.58 | $-2.40 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.